about us
CHENGDU SHENGNUO BIOPHARMACEUTICAL
Chengdu Shengnuo Biopharm Co., Ltd. (hereinafter referred to as “Shengnuo Biopharm”) is a wholly-owned subsidiary of Chengdu Shengnuo Biotechnology Co., Ltd. It was established in October, 2004 and is regarded as a "High-tech Enterprise Certified by Sichuan Province" and a "Sichuan Provincial Enterprise Technology Center". With a registered capital of 50 million yuan, it possesses over 50 key technologies for the large-scale production of peptides that have been marketed both domestically and internationally. It is a mature professional enterprise in China for the large-scale production of peptides and amino acid drugs, with a single batch output reaching the kilogram level and has passed the US FDA certification.
Chengdu Shengnuo Biopharm Co., Ltd. is a specialized, sophisticated, and innovative enterprise and a national high-tech enterprise specializing in the peptide field, which went public in 2021. We integrate R&D, production, and sales, with business covering peptide active pharmaceutical ingredients (APIs), cosmetic bioactive peptides, CDMO services, and peptide formulations. As a leading company in China's peptide API sector, we focus on the development, production, and technical services of peptide drugs, possessing full industrial chain capabilities from drug discovery to commercial manufacturing.
Company incorporation
Capital of 50 million yuan
More than 50 key technologies
Global partners
Peptide R&D Center
The center has been deeply involved in the field of peptides for more than 20 years, and has peptide API process research laboratories with a total area of 3,000 square meters, peptide API pilot plants with a total area of 1,500 square meters, GMP grade workshops for peptide API and topical drug development with a total area of 3,000 square meters, and drug development and analysis laboratories with a total area of 5,200 square meters. It has a professional R&D team of over 400 staff, and has successively carried out more than ten national and provincial scientific research projects, such as the National Major Special Project for Innovative Drug, covering multiple treatment areas including digestive system, immunity, tumor, hepatitis B, diabetes and obstetrics, and has obtained approval of more than 20 drugs, and plays an important role in promoting the development of China's peptide drug research and industrialization.
Four major production bases
Expert team
Expert Group for the Practice of Peptide Pharmacy Research
Innovative Drug and Generic Drug Development
Synthesis and Modification of Highly Complex Peptides
Purification of Complex Peptides
Synthetic Process Research and Optimization
Mass Production and Quality Control
Drug Application and Registration
An average of 15+ years of research and practical experience in peptide synthesis
Sichuan Province's top talent introduction of leading innovative and entrepreneurial teams
Provide CDMO services for more than 50 innovative drugs, several of which have been approved and marketed, and more than 30 of which are in clinical trials.
Lead 5 "Eleventh Five-Year" National Major Special Project for Innovative Drug: Atosiban Acetate, Octreotide Acetate, Somatostatin, Thymalfasin (thymosin alpha 1) and Carbetocin. All of them achieved commercially produce.
Completion of two domestic First Approved Generic Drugs: Enfuvirtide for injection and Carbetocin injection.
Complete the synthesis and mass production of several highly complex peptide drugs such as Liraglutide, Semaglutide, Tirzepatide and Enfuvirtide.
CORPORATE CULTURE
mission
Devoting to the peptide industry, safeguarding life and health.
vision
Innovation leads development, becoming the leader in the peptide industry.
core values
Customer first, win-win cooperation. People-oriented, co-creation and sharing.
Development History
2023
2023
2023
2023
2023
2023
2023
International first-class production environment and equipment
Patents and Technologies
Global leading QA system
industry influence
Business coverage of partners and markets